| Literature DB >> 33200042 |
Edwin Dovigi1, Elaine Yuen Ling Kwok2, Joseph C English3,4.
Abstract
Purpose of Review: Telemedicine use in dermatology, termed "teledermatology", offers a cost-effective model to improve healthcare efficiency and access. Only a minority of dermatology practices has integrated teledermatology into their practice prior to COVID-19. A thorough understanding of the barriers and facilitators may promote teledermatology adoption. Implementation science frameworks offer theoretically driven ways to assess factors affecting teledermatology implementation. This review uses a comprehensive implementation science framework to summarize barriers and facilitators of teledermatology implementation and appraises the quality of existing research. Recent Findings: Technological characteristics of teledermatology (e.g., user-friendliness) and factors within the outer setting (e.g., reimbursement and legal considerations) were the most commonly reported barriers. No existing studies use a comprehensive implementation framework to identify factors influencing teledermatology implementation. Many included studies have a risk of bias in at least two of the five study quality indices evaluated. Summary: This systematic review is the first study to summarize the existing teledermatology implementation literature into well-defined constructs from a comprehensive implementation science framework. Findings suggest future studies would benefit from the use of an implementation framework to reduce study bias, improve result comprehensiveness, facilitate comparisons across studies, and produce evidence-based resolutions to implementation barriers. Tools, resources, and recommendations to facilitate the use of an implementation framework in future studies are provided. Supplementary Information: The online version contains supplementary material available at 10.1007/s13671-020-00323-0. © Springer Science+Business Media, LLC, part of Springer Nature 2020.Entities:
Keywords: COVID-19; Dermatology; Teledermatology; Telemedicine
Year: 2020 PMID: 33200042 PMCID: PMC7658914 DOI: 10.1007/s13671-020-00323-0
Source DB: PubMed Journal: Curr Dermatol Rep ISSN: 2162-4933
Fig. 1PRISMA flowchart for study inclusion
Characteristics of included studies
| First author (year) | Front-end user of teledermatology | Telehealth practice format | Reported use of implementation theory? | Country | Number of teleconsults | Number and type of survey participants | Number of study quality indices with risk of bias |
|---|---|---|---|---|---|---|---|
| Armstrong (2010) [ | Healthcare provider | SAF | No | USA | NA | 8 dermatologists; interview | 2 |
| van der Heijden (2014) [ | Healthcare provider | SAF | No | Netherlands | 85 | 13 dermatologists; questionnaire and interview | 4 |
| van der Heijden (2010) [ | Healthcare provider | SAF | No | Netherlands | 28 | 20 dermatologists; questionnaire | 2 |
| Kips (2019) [ | Healthcare provider | SAF | No | Belgium | 54 | 15 mixed (12 primary care providers; 3 dermatologists); questionnaire | 3 |
| Delaigue (2014) [ | Healthcare provider | SAF | No | 24 different countries | Not reported | 22 mixed (13 dermatologists and 9 non-dermatologist healthcare providers); questionnaire | 3 |
| Lasierra (2012) [ | Healthcare provider | SAF | No | Spain | 17 | 14 mixed (13 primary care providers, 1 dermatologist); questionnaire | 3 |
| Orruño (2011) [ | Healthcare provider | SAF | Yesa | Spain | 254 | 161 mixed (16 dermatologists, 126 family medicine physicians, 19 pediatricians); questionnaire | 2 |
| Janda (2019) [ | Healthcare provider | SAF | Yesa | Australia (85%), Europe (7%) | Not reported | 52 mixed (16 primary care providers, 22 dermatologists, 14 dermatologist registrars); survey | 1 |
| Ford (2019) [ | Healthcare provider | SAF | No | USA | Not reported | 29 mixed (17 patients, 8 primary care providers and 4 dermatologists); interview | 2 |
| Manahan (2011) [ | Healthcare provider | SAF | No | Australia | 2 | 21 mixed (19 pharmacists, 2 patients); questionnaire | 2 |
| Kaliyadan (2013) [ | Healthcare provider | SAF | No | Saudi Arabia | 166 | 25 mixed (23 patients, 2 dermatologists); questionnaire | 3 |
| Ludwick (2010) [ | Healthcare provider | SAF | No | Canada | 28 | 10 mixed (9 physicians, 1 dermatologist); interview | 2 |
| von Wangenheim (2019) [ | Healthcare provider | SAF | No | Brazil | 83,100 | NA; NA | Retrospective chart review, not assessed |
| Nakayama (2012) [ | Healthcare provider | SAF | No | Japan | 36 | 23 pathologists; questionnaire | 4 |
| Spinks (2016) [ | Healthcare provider | SAF | No | Australia | Not reported | 35 patients; direct choice experiment | 3 |
| Armstrong (2012) [ | Healthcare provider | SAF and LI | No | USA | 2760 | 10 primary care providers; interview | 1 |
| Barbieri (2015) [ | Healthcare provider | Not reported | No | USA | Not reported | 18 primary care providers; survey | 3 |
| O’Toole (2017) [ | Healthcare provider | SAF | No | Canada | 965 | 217 primary care providers; survey | 3 |
| Costello (2019) [ | Healthcare provider | SAF | No | USA | 38 | unknown number of primary care providers; survey | 3 |
| Eber (2019) [ | Mix (healthcare provider and patient) | Not reported | No | Austria | Not reported | 243 dermatologists; questionnaire | 2 |
| Ariens (2017) [ | Patients | SAF and LI | No | Netherlands | Not reported | 39 dermatologists; survey | 2 |
| Wu (2015) [ | Patients | SAF | No | USA | Not reported | 31 mixed (2 dermatologists, 29 patients); survey | 4 |
| Fiks (2018) [ | Patients | SAF | No | USA | Not reported | 135 patients; survey | 3 |
| Kong (2020) [ | Patients | SAF | No | Australia | Not reported | 28 patients; interview | 3 |
| Pathipati (2016) [ | Patients | SAF | No | USA | 38 | 38 patients; interview | 4 |
| Horsham (2016) [ | Patients | SAF | Yesa | Australia | 49 | 49 patients; survey | 2 |
| Al Quran (2015) [ | Patients | LI | No | Jordan | 90 | 88 patients; interview | 2 |
| Armstrong (2011) [ | Unclear | SAF and LI | No | USA | Not reported | 17 dermatologists; interview | 2 |
| Walters (2018) [ | Unclear | Not reported | No | South Africa | NA | NA; NA | 2 |
| Romero (2018) [ | Unclear | SAF and LI | No | Spain | Not reported | Not reported (providers drawn from 42 dermatology centers); NA | 2 |
SAF store and forward, LI live interactive
aTechnology acceptance model
Major barriers and facilitators to teledermatology across studies
| CFIR domains | Barriers | Facilitators |
|---|---|---|
| Domain 1: intervention characteristics | ||
| Relative advantage | Teledermatology offers less clinical information than in person clinic visits (e.g., history, outcome, images) Communication challenges, including: providing diagnoses, offering emotional support and advice, having a dialog | Improved efficiency and convenience (e.g., reduced wait and travel time) Improved access to care Teledermatology improves patients’ and primary care providers’ knowledge of skin disorders |
| Design quality and packaging | Technological limitations of teledermatology | Easy to use and intuitive technology |
| Cost | Time required to learn to use the technology | |
| Domain 2: outer setting | ||
| Patient needs and resources | Teledermatology cannot address some skin conditions Patients do not wish to be photographed due to social and religious reasons | Teledermatology meets the needs of patients |
| External policy and incentives | Reimbursement concerns Providers also reported increased medical liability and risk of privacy breach | |
| Domain 3: inner setting | ||
| Compatibility | Teledermatology not compatible with existing workflow, health record system, and organizational policy | Teledermatology aligns with existing workflow and clinical needs |
| Available resources | Lack of time, personnel, equipment to adopt teledermatology | Availability of trainings, personnel and infrastructures |
| Domain 4: characteristics of individual | ||
| Self-efficacy | Lack of confidence in taking images of lesion, following recommendations from dermatologists. | Improved primary care provider and patient self-confidence in managing skin diseases |
| Knowledge and beliefs | Belief that teledermatology is not as accurate as in-person consultation | Beliefs in the usefulness of teledermatology |
| Domain 5: process | ||
| External change agents | No studies reported barriers in this domain | Involving experts with experience in teledermatology implementation |